复星医药(02196.HK) 公布,集团自主研发的伊匹木单抗生物类似药HLX13(重组抗 CTLA-4全人单株抗体注射液)第一线治疗不可切除的晚期肝细胞癌(HCC)患者于中国境内启动I/III期临床试验。HLX13拟用于治疗黑色素瘤、肾细胞癌、大肠直肠癌、肝细胞癌、非小细胞肺癌症、恶性胸膜间皮瘤及食道鳞状细胞癌。截至今年4月,集团现阶段针对HLX13累计研发投入约为1.04亿元人民币。(sl/a)...
Source Link复星医药(02196.HK) 公布,集团自主研发的伊匹木单抗生物类似药HLX13(重组抗 CTLA-4全人单株抗体注射液)第一线治疗不可切除的晚期肝细胞癌(HCC)患者于中国境内启动I/III期临床试验。HLX13拟用于治疗黑色素瘤、肾细胞癌、大肠直肠癌、肝细胞癌、非小细胞肺癌症、恶性胸膜间皮瘤及食道鳞状细胞癌。截至今年4月,集团现阶段针对HLX13累计研发投入约为1.04亿元人民币。(sl/a)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.